Corrigendum to: Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Corrigendum to: Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2

Published:2023 Issue:2 Volume:2 Page:
ISSN:2737-7946
Container-title:Acta Materia Medica
language:en
Short-container-title:

Author:

Zhang Shi-Bing¹²,Hong Ming³,Sun Xiao-Yang¹,Huang Da¹,He Dan-Hua¹,Chen Yu-Fei¹,Yuan Yong³,Liu Yong-Qiang¹

Affiliation:

1. Key Laboratory of Chinese Medicinal Resource from Lingnan (Guangzhou University of Chinese Medicine), Ministry of Education; Research Center of Chinese Herbal Resources Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

2. Institute of Clinical Pharmacology, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

3. Institute of Advanced Diagnostic and Clinical Medicine, Zhongshan People’s Hospital, Zhongshan 528403, China

Publisher

Compuscript, Ltd.

Link

https://scienceopen.com/document_file/1cfb9a28-9980-44fd-884c-ad5bb72718fc/ScienceOpen/amm20231001.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted co-delivery of curcumin and erlotinib by MoS2 nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer;Journal of Nanobiotechnology;2023-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP